NASHUA, N.H. - iCAD, Inc. (NASDAQ: NASDAQ:ICAD), a company specializing in AI-powered cancer detection solutions, announced today the FDA clearance of ProFound Detection Version 4.0 for Digital Breast Tomosynthesis (DBT). This latest AI software iteration showcases advanced deep learning technology and has demonstrated a 6.3% improvement in the area under the receiver operating characteristic curve (AUC) compared to its predecessor, enhancing its ability to detect aggressive cancers and reduce false positives.
The newly approved version also introduces the capability for clinicians to include past exam data in the current exam's analysis, potentially increasing diagnostic accuracy. The FDA's authorization allows iCAD to offer the software for use in the United States immediately, with additional regulatory approvals expected globally and vendor-specific expansions anticipated through 2025.
ProFound Detection Version 4.0 is built on over two decades of iCAD's experience and continues the company's legacy as an innovator in the field, being the first to introduce an FDA-cleared AI solution for DBT in 2016. The software's improvements include a 22% overall increase in the detection of challenging cancer subtypes, with significant enhancements in identifying cancers in dense breast tissue and invasive lobular cancers.
The company anticipates that the adoption of ProFound Detection Version 4.0 and its cloud-based deployment will contribute to steady growth in Annual Recurring Revenue (ARR). This strategic move towards cloud services is expected to offer healthcare facilities continuous updates and improved operational efficiency.
Dr. Chirag Parghi, MD, MBA, Chief Medical (TASE:PMCN) Officer at Solis Mammography, praised the new version's ability to detect invasive cancers within dense breast tissue, a major challenge in breast imaging. He also noted that the software's improved precision and the inclusion of prior exams in the analysis could lead to more efficient reading workflows and broader AI adoption.
iCAD will present ProFound Detection Version 4.0 and its complete breast health AI suite at the upcoming 2024 Radiological Society of North America (RSNA) annual meeting in Chicago.
The information in this article is based on a press release statement from iCAD, Inc.
In other recent news, iCAD Incorporated reported a notable 21% revenue increase in the second quarter of 2024, compared to the same period last year, reaching $5 million. This growth is attributed to the company's strategic transition to a Software (ETR:SOWGn) as a Service (SaaS) platform, coupled with its expansion of customer base to over 4,000 across 50 countries. Additionally, iCAD has secured strategic partnerships with Windsong Radiology, Steinberg Diagnostic, among others, further enhancing its market position.
The company's ProFound Cloud Platform, built on the Google (NASDAQ:GOOGL) Cloud Platform, is anticipated to boost profitability and cash flow. A recent study showcased iCAD's ProFound AI outperforming other AI systems, demonstrating an Area Under the Curve (AUC) of 0.93. Despite the revenue growth, the company reported a GAAP net loss of $1.7 million and a non-GAAP adjusted EBITDA loss of $1.2 million.
iCAD finished the quarter with $20.4 million in cash and cash equivalents, and its Annual Recurring Revenue (ARR) reached $9.2 million. The company anticipates its shift to a recurring revenue model to provide better business visibility and more effective expense management. These recent developments underscore iCAD's commitment to innovation and growth in the AI healthcare market.
InvestingPro Insights
iCAD's recent FDA clearance of ProFound Detection Version 4.0 aligns with the company's strong market position in AI-powered cancer detection solutions. According to InvestingPro data, iCAD boasts impressive gross profit margins of 87.08% for the last twelve months as of Q2 2024, reflecting the high-value nature of its AI software offerings. This is further supported by an InvestingPro Tip highlighting the company's "impressive gross profit margins."
The company's focus on innovation and continuous improvement of its AI solutions is reflected in its recent stock performance. InvestingPro data shows a significant 44.52% price return over the last month and a 57.46% return over the past three months. This positive momentum could be attributed to investor optimism surrounding iCAD's technological advancements and market potential.
However, it's worth noting that despite these positive indicators, iCAD faces some financial challenges. An InvestingPro Tip reveals that the company "holds more cash than debt on its balance sheet," which could provide financial flexibility as it continues to invest in research and development. Additionally, the company's revenue for the last twelve months as of Q2 2024 stands at $18.8 million, with a revenue growth of 7.4% over the same period.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for iCAD, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.